What is the Epigral PE ratio today?
Epigral's PE ratio is 14.4 at the previous close (₹902.40 a share): a market capitalisation of ₹3,893 crore divided by consolidated net profit of ₹271 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹332 crore) it is 11.7.
What is the Epigral net worth?
Epigral's net worth — shareholders' equity in its consolidated balance sheet — was ₹2,221 crore on 31 March 2026, up 16.6% from ₹1,905 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,893 crore at the previous close.
What is the Epigral book value per share?
Epigral's book value per share was ₹514.94 on 31 March 2026: shareholders' equity of ₹2,221 crore divided by the 4.31 crore shares in issue, up 16.6% from ₹441.48 a year earlier. The share price at the previous close was ₹902.40.
What is the Epigral PB ratio (price to book value)?
Epigral's price-to-book (PB) ratio is 1.75 at the previous close: a market capitalisation of ₹3,893 crore divided by shareholders' equity (book value) of ₹2,221 crore on 31 March 2026. That is a book value of ₹514.94 per share against a share price of ₹902.40.
Is Epigral debt free?
No. Epigral had borrowings of ₹563 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.25. Its cash and current investments were ₹5.5 crore, so its net debt was ₹558 crore.
What is the Epigral ROE and ROCE?
In FY26, Epigral's return on equity (ROE) was 16.1% and its return on capital employed (ROCE) was 14.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 22.7% and ROCE 24.7%.
What is the Epigral market cap?
Epigral's market capitalisation was ₹3,893 crore at the previous close: 4.31 crore shares at ₹902.40 each.
What is the Epigral EPS?
Epigral's basic earnings per share (EPS) were ₹76.95 in FY26, against ₹84.68 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹62.82.
What is the Epigral dividend in 2026 and its record date?
In 2026, Epigral has declared one dividend: ₹5 with record date 1 June 2026.
What is the Epigral debt to equity ratio?
Epigral's debt-to-equity ratio was 0.25 on 31 March 2026: borrowings of ₹563 crore against total equity of ₹2,221 crore. A year earlier, on 31 March 2025, it was 0.31.
What is the Epigral dividend yield?
Epigral's dividend yield is 0.55% at the previous close: dividends of ₹5 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹902.40. They were ₹5 on 1 June 2026.
What is the Epigral promoter holding?
Promoters held 68.83% of Epigral on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Epigral shareholding pattern?
On 30 September 2026, Epigral's shares were held by promoters 68.83%, foreign portfolio investors (FII/FPI) 0.99%, domestic institutions (DII) 4.90% (including mutual funds at 4.87%) and retail and other non-institutional investors 25.26%. Over the year, FII holding was down 1.72 percentage points from 2.71% and DII holding was down 0.02 percentage points from 4.92%.
What is the Epigral revenue and profit in FY26?
In FY26 (April 2025–March 2026), Epigral's consolidated net profit was ₹332 crore, down 7.2% from ₹358 crore in FY25, on revenue from operations of ₹2,527 crore (down 0.9%). Over three years, from FY23, net profit was down 6.0%.
Epigral vs Yasho Industries: how do they compare?
In FY26, Epigral earned net profit of ₹332 crore on revenue of ₹2,527 crore, against ₹25.3 crore on ₹830 crore for Yasho Industries. Epigral's operating margin was 15.8% (Yasho Industries 10.7%) and its return on equity 16.1% (Yasho Industries 5.9%).
What is the Epigral free cash flow?
In FY26, Epigral generated ₹436 crore of cash from operations and spent ₹394 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹41.4 crore. In FY25 it was ₹246 crore.
What are the Epigral latest quarterly results?
Epigral's latest results are for Q1 FY27 (April–June 2026), filed on 27 July 2026: consolidated net profit ₹99.7 crore, down 37.9% from ₹161 crore in Q1 FY26; revenue from operations ₹705 crore, up 16.3% year on year.
When are the Epigral next results?
Epigral will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
How does Epigral compare with its peers?
On FY26 consolidated figures, against Yasho Industries, Gujarat Alkalies and Chemicals and Fineotex Chemical: Epigral's operating margin of 15.8% is the highest of the four (Yasho Industries 10.7%, Gujarat Alkalies and Chemicals −0.2%, Fineotex Chemical 15.7%; peer average 8.7%); its return on equity of 16.1% is the highest of the four (Yasho Industries 5.9%, Gujarat Alkalies and Chemicals −0.0%, Fineotex Chemical 13.5%; peer average 6.4%).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
